Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010

QJM: An International Journal of Medicine

Volumn 100, Issue 5, 2007, Pages 277-289

  Fidan, D ^a,d   Unal, B ^a,b   Critchley, J ^c   Capewell, S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RETEPLASE; SIMVASTATIN; SPIRONOLACTONE; STREPTOKINASE; TENECTEPLASE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CALCULATION; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HOSPITAL COST; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

EID: 34447333369     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm020     Document Type: Article

References (41)

1. British Heart Foundation Statistics Database. Coronary Heart Disease Statistics. 2002. [http://www.bhf.org.uk/professionals/uploaded/ bhf%20heartstats%202003%20-%204-page.pdf] Accessed 13 October 2006.
2. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277:535-42.
3. Unal B, Critchley J, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981-2000. Circulation 2004;109:1101-7.
4. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005;162:764-73.
5. Bennett K, Kabir Z, Unal B, Shelley E, Critchley J, Perry I, et al. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Comm Health 2006;60 322-7.
6. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000;102:1511-16.
7. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002; 88:597-603.
8. Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92 1384-9.
9. Boyle R. Delivering better heart services: NSF services progress report 2003. [http://www.dh.gov.uk/assetRoot/04/07/52/80/04075280.pdf] Accessed 2 May 2006.
10. BHF Statistics Website: Prescriptions. [http://www.heartstats.org] Accessed 25 May 2006.
11. All Parliamentary Group on Heart Disease. [www.bhf.org.uk/appg/] Accessed 25 May 2006.
12. NHS Centre for Reviews and DisseminationCholesterol and coronary heart disease: Screening and treatment. Effective Health Care Bull 1998;4:1-16.
13. Pickin DM, McCabe C, Ramsay JG, Payne N, Haq IU, Yeo WW,et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82:325-32.
14. Cleland JG, Walker A. Therapeutic options and cost considerations in the treatment of ischemic heart disease. Cardiovasc Drugs Therapy 1998;12 (Suppl. 3):225-32.
15. Weinstein MC. Coronary Artery bypass surgery is still costeffective: using calibrated models to update clinical trials. Am J Med 2003;115:410-11.
16. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:769-79.
17. Favarato D, Hueb W, Gersh BJ, Soares PR, Cesar LA, da Luz PL, et al Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study. Circulation 2003; 108(Suppl. 1):II21-3.
18. Fox KF, Wood DA, Wright M, Bond S, Nuttall M, Arora B, et al. Evaluation of cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. J Cardiovasc Risk 2002;9:355-9.
19. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999;81:380-6.
20. Capewell S, Beaglehole R, Seddon M, McMurray J. Explaining the decline in Coronary Heart Disease Mortality in Auckland, New Zealand between 1982 and 1993. Circulation 2000;102:1511-16.
21. Unal B, Critchley J, Fidan D, Capewell S. Life-years gained from modern cardiological treatments and population risk factor changes in England and Wales, 1981-2000. Am J Public Health 2005;95:103-8.
22. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004;110:1236-44.
23. Unal B, Critchley J, Fidan D, Capewell S. Life-years gained from modern cardiological treatments and population risk factor changes in England and Wales, 1981-2000. Am J Public Health 2005;95:103-8.
24. Taylor RS, Brown A, Ebrahim S, Jolliffe JA, Noorani H, Rees K, et al The effectiveness of exercise based interventions for patients with coronary heart disease: Systematic review and meta-analysis of randomised controlled trials. Am J Med 2004;116:682-92.
25. NHS Reference Costs. London, Department of Health, 2000.
26. British National Formulary, No. 40. London, HMSO, 2000.
27. Myocardial infarction-early thrombolysis treatment. NICE Appraisal Guidance No. 52, 2004.
28. Gray AM, Bowman GS, Thompson DR. The cost of cardiac rehabilitation services in England and Wales. J Roy Coll Phys London 1997;31 57-61.
29. Guide to the Technology Appraisal Process (reference N0514). National Institute for Clinical Excellence, 2004.
30. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ 1994;3:95-104.
31. Capewell S, Unal B, Critchley J, McMurray JJ. Over 20 000 avoidable coronary deaths in England and Wales in 2000: The failure to give effective treatments to many eligible patients. Heart 2006;32 521-3.
32. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Ann Intern Med 2006;144:326-36.
33. Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID study. Am Heart J 2006;151:1305-12.
34. Franco OH, Peeters A, Looman CW, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005;59:927-33.
35. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: Modelling study. Br Med J 2006; 332:1419.
36. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart2001; 85:539-43.
37. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG,et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.[comment].N Engl J Med 2002; 346:1800-6.
38. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
39. Phillips CJ, Prowle MJ. Economics of a reduction in smoking: Case study from Heartbeat Wales. J Epidemiol Community Health1993;47 215-23.
40. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: Is individual intervention worth while? Br Med J 1991;302:1119-22.
41. Goldman L, Phillips KA, Coxson P, Goldman PA, Williams L, Hunink MG, et al. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol 2001;38:1012-17.